

## CURRICULUM VITAE

**Garnet L. Anderson**

**Office:** Fred Hutchinson Cancer Research Center  
1100 Fairview Ave N, M3-A410  
PO Box 19024  
Seattle, WA 98109  
(206) 667-4699 voice  
(206) 667-4142 fax

**E-mail:** garnet@whi.org

**Home:** 727 33rd Avenue  
Seattle, WA 98122-5122  
(206) 328-4175

**Education:** University of Washington, Seattle, Washington, Ph.D., Biostatistics, 1989  
State University of New York, Binghamton, New York, M.A., Mathematical Sciences,  
1983  
Northwest Nazarene College, Nampa, Idaho, B.S., summa cum laude, Mathematics, 1981

### POSITIONS:

Member, Cancer Prevention Research Program and Biostatistics Program, Public Health Sciences  
Division, Fred Hutchinson Cancer Research Center, 2002 - present.

Affiliate Professor, Department of Biostatistics, University of Washington, 2005-present.

Principal Investigator (with Ross Prentice), Women's Health Initiative Clinical Coordinating  
Center, October 2008-present.

Principal Investigator (with Andrea LaCroix), MsFLASH network, August, 2008-present

Associate Director for Cancer Control and Prevention, Southwest Oncology Group Statistical  
Center, 2008 – present.

Associate Program Head, Gynecologic Cancer Research Program, Fred Hutchinson Cancer  
Research Center, 2002 - 2007.

Co-Principal Investigator and Project Director, Women's Health Initiative Clinical Coordinating  
Center, October 1998-2008.

Affiliate Associate Professor, Department of Biostatistics, University of Washington, 1997-2005.

Associate Member, Biostatistics Program, Fred Hutchinson Cancer Research Center, 1995-2001.

Affiliate Assistant Professor, Department of Biostatistics, University of Washington, April 1989 -  
1997.

Assistant Member, Biostatistics and Cancer Prevention Research Program, Fred Hutchinson  
Cancer Research Center, January 1989 - May 1995.

### PROFESSIONAL ACTIVITIES:

#### Institute of Medicine:

2006 Report Reviewer, Committee on the Disposition of the Air Force Health Study Board on  
Population Health and Public Health Practices

2004 Member, Committee on the Review of National Immunization Program's Research  
Procedures and Data Sharing Program

#### Food and Drug Administration:

Anderson GL

2009-present: Member, Gastrointestinal Drug Advisory Committee

International Agency for Research on Cancer:

2005 Member, Working Group on oestrogen-progestogen replacement therapy and combined oral contraceptives.

European Commission:

2009-2010: Review panel member; Harmonisation of phenotyping and biosampling for human large-scale research biobanks.

Refereeing:

Annals of Internal Medicine	Heart
American Statistician	Journal of the American Medical Association
Biometrika	Journal of the American Statistical Association
Biometrics	Journal of Clinical Oncology
Cancer	Journal of General Internal Medicine
Circulation	Journal of Molecular Diagnostics
Clinical Cancer Research	Journal of the National Cancer Institute
Controlled Clinical Trials	Maturitas
European Journal of Obstetrics, Gynecology and Reproductive Biology	Nature Clinical Practice/Oncology
Health Services Research	Scandinavian Journal of Statistics
	The Cochrane Library

NIH/CDC service:

2010 Ad hoc Reviewer, Subcommittee H, NCI  
2008-present, Member, Gynecological Cancer International Group  
2008-present, Member, Gynecological Cancer Steering Committee and Ovarian Task Force  
2006 Member, Cardiovascular Strategic Planning Level 1: Clinical Trial Design, NHLBI  
2004 Ad hoc Reviewer, Cancer Centers, NCI  
2003 Ad Hoc Reviewer, Cancer Centers, NCI  
2003 CDC, Ovarian Cancer Workshop Expert Panel  
2003 Ad hoc Reviewer, Clinical Groups, NCI  
2002 Scientific Review Group, (Cancer Center grant) NCI  
2002 Special Emphasis Panel, SPORES in Gynecologic Cancers, NCI  
2001-02 NCI Gynecologic Cancer Progress Review Group  
2001 Scientific Review Group, (UO1) NCI  
1998 Special Emphasis Panel, Breast and Prostate Cancer SPORES (P50) NCI  
1998 Special Emphasis Panel (PO1), NCI  
1997 Administrative Review Panel (UO1), NIA  
1995 Special Emphasis Panel, Breast Cancer SPORE Grants (P20/50), NCI  
1993 Biological Response Modifiers (UO1), NCI  
1991 Cancer Prevention and Control Program Project (PO1), NCI

Data and Safety Monitoring Boards/Advisory Boards

2010-present, Member, Data and Safety Monitoring Board for the NIA sponsored ASPirin in Reducing Events in the Elderly (ASPREE) funded by the NIA and Australian Health Authority.  
2010-present, Chair, Data and Safety Monitoring Board for the NIA sponsored Partnership for Anemia: Clinical and Translational Trials in the Elderly consortium (PACTTE)  
2010-Member, NHLBI Protocol Review Committee for PROspective Multicenter Imaging Study for Evaluation of Chest Pain (PROMISE)

Anderson GL

2008-present, Member, Data and Safety Monitoring Board for the NCI sponsored National Surgical Adjuvant Breast and Bowel Project (NSABP) cooperative oncology group

2007-present, Member, Data and Safety Monitoring Board for the NICHD sponsored trial: Effects of Aspirin in Gestation and Reproduction Study (EAGeR)

Fred Hutchinson Cancer Research Center:

Member, SWOG Group Statistician Search Committee (2009-2010)

Member, 5-year Review Committee for Nicole Urban (2009)

Member, Biostatistics Search Committee (2008)

Member, Epidemiology Search Committee (2008)

Member, 5-year Review Committee for CY Wang (2008)

Chair, Promotion Review Committee for Catherine Tangen (2008)

Pilot Grant Review Committee (2005-2006)

Clinical Trials Affinity Group Leader (2003-present)

Research Ethics Committee (2003-2007)

Associate Program Heads (2002-2007)

Scientific Steering Committee (2002-present)

Faculty Ombudsperson Committee (2002)

PHS Improvement Committee (1998)

PHS Computing Committee (1994-2000)

Women's Health Initiative:

Member, Ancillary Study Committee (2005-present)

Member, Executive Committee and Steering Committee (2004-present)

Member, Case-Control Analyte/Core Studies Working Group (2002-present)

Member, Close-out Working Group (2001-2003)

Chair, Design and Analysis Committee (2001-2005)

Member, Blood Biomarker Task Force (1999)

Member, Reorganization Task Force (1998)

Participant, DM Adherence Summit (1998)

Participant, HRT Adherence Summit (1997)

Chair, Steering Committee (1997-1998)

Co-Chair, Steering Committee (1996-1997)

Co-Chair, Quality Assurance Task Force (1996)

Member, Performance Monitoring Committee (1995-1998)

Member, Streamlining Task Force member (1994, 1995, 1997)

Member, Design and Analysis Committee (1993-1996, 1997-2000)

Member, Executive Committee (1993-1994)

Chair, Operations Committee (1993-1994)

Chair, Data Management Working Group Chair (1993-1994)

Marsha Rivkin Center for Ovarian Cancer Research/Pacific Ovarian Cancer Research Consortium (NCI SPORE):

Reviewer, POCRC Developmental Research Program, 2010

Co-chair, SPORE Preconference Workshop: Strategies for implementing biomarker evidence in translational cancer research, 2007

Member, Organizing Committee for the SPORE Preconference Workshop on Statistical Methods for Clinical Trials and Biomarkers, 2006

Member, Planning Committee, 4th Annual International Ovarian Cancer Screening Meeting, 2001

Co-Chair, Ovarian Inter-SPORE Informatics Committee, 2000-2005

Member, Specimen Use Committee, 2001-2009

Anderson GL

Member, POCRC Planning Committee, 1999

Southwest Oncology Group

Gynecological Cancer Committee Statistician, 2008-2010  
Statistical Center Associate Director for Cancer Control and Prevention, 2008-present  
Statistical Center Data Quality Improvement Committee Chair 2007-2008  
Gastrointestinal Cancer Committee Statistician, 2006-2008

Menopausal Symptoms-Finding Lasting Answers to Sweats and Hot Flashes (MsFLASH) Network

Member, Network Steering Committee, 2008-present

Other Professional Service:

Member, Editorial Board, Cancer Prevention, 2009-present  
Reviewer, Quinquennial review for Dr. Valerie Beral, 2009  
Reviewer, Quinquennial review for Dr. Peter Sasieni, 2008  
Co-Organizer, American Association for the Advancement of Science session, 2004  
Associate Editor, Clinical Journal of Women's Health, 2000-2002.  
Associate Editor, Controlled Clinical Trials, 1994-1999  
WNAR Regional Advisory Board, 1992-1995

**AWARDS:**

A. Marsh Poulson, Jr. MD Lectureship, 2003  
WHI Achievement Award, 1996, 1997  
Computerworld Smithsonian Award, 1995  
Best Presentation, 1988 WNAR student paper competition  
Donovan Thompson Biomathematics Student Award, Department of Biostatistics, University of Washington, 1984  
Cardiovascular Traineeship, Department of Biostatistics, University of Washington, 1984-1988  
President's Scholarship, Northwest Nazarene College, Nampa, Idaho, 1977-1981

**TEACHING/MENTORING:**

Lectures:

Guest Lecturer, Epidemiology, Epidemiological Methods (Epi 513), Department of Epidemiology, University of Washington, 2010.

Guest Lecturer, Case-based Social Statistics (Stat 322), Department of Statistics, University of Washington, May 2009.

AACR Cancer Biostatistics Workshop. Cancer Prevention Trials: A Statisticians Perspective, Sonoma CA, 2008

Clinical Trials: A Practical Guide to Design, Implementation, Analysis and Reporting. Seattle ERIC Epidemiology, Biostatistics and Clinical Research Methods Summer Session, 2005.

Advanced Topics in Clinical Trials. Seattle ERIC Epidemiology, Biostatistics and Clinical Research Methods Summer Session, 2003.

Guest Lecturer, Biostatistics 514, Department of Biostatistics, University of Washington, 2003

Student Advising:

Graduate Faculty Representative, Sheetal Hardikar, Department of Epidemiology, current

Anderson GL

Committee Member, Alicia Sato, Department of Biostatistics, MS, 2004  
Committee Member, Casey Crump, Department of Biostatistics, MS, 1998

PhD Exam committee: Lars Hougaard Nielsen, University of Copenhagen, 2010

Member, Junior Faculty Mentoring Committee: Katherine Guthrie, Mary Redmond; Megan Othus

## **PUBLICATIONS:**

1. NCI Breast Cancer Screening Consortium. Screening mammography: A missed clinical opportunity? *JAMA* 264(1):54-58, 1990.
2. Stergachis A, Shy KK, Grothaus LG, Wagner EH, Hecht JA, *Anderson GL*, Normand E, Raboud J. Tubal sterilization and the long-term risk of hysterectomy. *JAMA* 264(22):2893-2898, 1990.
3. Omenn GS, Goodman G, Grizzle J, Thornquist M, Rosenstock L, Barnhart S, *Anderson GL*, et al. CARET, the Beta-Carotene and Retinal Efficacy Trial to prevent lung cancer in asbestos-exposed workers and in smokers. *Anti-Cancer Drugs* 2:79-86, 1991.
4. Pepe MS and *Anderson GL*. Two stage experimental designs: Early stopping with negative results. *Applied Statistics* 41(1):190-191, 1992.
5. Kristal AR, White E, Shattuck AL, Curry S, *Anderson GL*, et al. Long-term maintenance of a low fat diet. Durability of fat-related dietary habits in the Women's Health Trial. *Journal of the American Dietetic Association* 92(5):553-559, 1992.
6. Urban N, White E, Anderson G, Curry S, Kristal A. Correlates of maintenance of a low fat diet among women in the Women's Health Trial. *Preventive Medicine* 21:279-291, 1992.
7. Omenn GS, Goodman G, Grizzle J, Thornquist M, Rosenstock L, Barnhart S, *Anderson G*, et al. Recruitment for CARET, the  $\beta$ -Carotene and Retinal Efficacy Trial to prevent lung cancer in smokers and in asbestos-exposed workers. *Western J Med* 156:540-544, 1992.
8. Shy KK, Stergachis A, Grothaus LG, Wagner EH, Hecht JA, *Anderson GL*. Tubal sterilization and risk of subsequent hospital admission for menstrual disorders. *American J Obstet Gynec* 166(6):1698-1705, 1992.
9. Brawner DL, *Anderson GL*, Yuen KY. Serotype prevalence of candida-alibicans from blood culture isolates. *J Clinical Microbiology* 30:149-153, 1992.
10. Mickelson E, Smith A, McKinney S, *Anderson GL*, Hansen JA. A comparative study of HLA-DRB1 typing by standard serology and hybridization of non-radioactive sequence-specific oligonucleotide probes to PCR-amplified DNA. *Tissue Antigens* 41:86-93, 1993.
11. Omenn GS, CARET Co-Investigators. CARET, the Beta-Carotene and Retinol Efficacy Trial to prevent lung cancer in asbestos-exposed workers and in smokers. *Sourcebook on Asbestos Diseases*, pp 219-241, 1993.
12. Rowley, SD, *Anderson G*:. Effect of dimethylsulfoxide exposure without cryopreservation on hematopoietic progenitor cells. *Bone Marrow Transplantation* 11(5):389-393, 1993.
13. Urban N, *Anderson GL*, Tseng A. Effects on response rates and costs of stamps vs business reply in a mail survey of physicians. *Journal of Clinical Epidemiology* 46(5):445-459, 1993.

14. Brodtkin CA, Barnhart S, *Anderson G*, Checkoway H, Omenn GS, Rosenstock L. Correlation between respiratory symptoms and pulmonary function in asbestos-exposed workers. *American Review of Respiratory Diseases* 148:32-37, 1993.
15. Thornquist MD, Omenn GS, Goodman G, et al. Statistical design of the Carotene and Retinol Efficacy Trial (CARET). *Controlled Clinical Trials* 14(4):308-324, 1993.
16. Bowen DJ, Henry H, Burrows E, *Anderson GL*, Henderson MH. Influences of eating patterns on low-fat dietary change. *Journal of the American Dietetic Association* 93(11):1309-1311, 1993.
17. Bearman SI, *Anderson G*, Mori M, Hinds MS, Shulman HM, McDonald GB. Venooclusive Disease of the liver: Development of a model for predicting fatal outcome after marrow transplantation. *Journal of Clinical Oncology* 11(9):1729-1736, 1993.
18. Urban N, *Anderson GL*, Peacock S. Mammography screening: How important is cost as a barrier to use? *American Journal of Public Health* 84(1):50-55, 1994.
19. Busca A, Anasetti C, *Anderson G*, Appelbaum FR, Buckner CD, Doney K, Martin PJ, Petersdorf E, Sanders JE, Hansen JA. Unrelated donor or autologous marrow transplantation for treatment of acute leukemia. *Blood* 83(10):3077-3084, 1994.
20. Pepe MS, *Anderson GL*. A cautionary note on inference for marginal regression models with longitudinal data and general correlated response data. *Communications in Statistics: Simulation and Computation* 23(4):939-951, 1994.
21. Anderson GL, Fleming TR. Model misspecification in proportional hazards regression. *Biometrika* 82(3):527-541, 1995.
22. Urban N, Taplin SH, Taylor VM, Peacock S, *Anderson G*, Conrad D, Etziono R, White E, Montano DE, Mahlock J, Majer K. Community organization to promote breast cancer screening among women ages 50-75. *Preventive Medicine* 24:477-484, 1995.
23. Kalhs P, Schwarzinger I, *Anderson GL*, Clift RA, Storb R, Buckner CD, Appelbaum FA, Hansen JA, Sullivan KM. A retrospective analysis of the long-term effect of splenectomy on late infections, graft-versus-host disease, relapse and survival following allogeneic marrow transplantation for chronic myelogenous leukemia. *Blood* 86(5):2028-2032, 1995.
24. Freedman L, *Anderson GL*, Kipnis V, Prentice R, Wang C.Y., Rossouw J, Wittes J, DeMets D. Approaches to monitoring the results of long-term disease prevention trials. *Controlled Clinical Trials* 17(6):509-525, 1996.
25. Goodman GE, Thornquist M., Kestin M, Metch B, *Anderson G*, Omenn GS. The association between participant characteristics and serum concentrations of  $\beta$ -carotene, retinol, retinyl palmitate and  $\alpha$ -tocopherol among participants in the Carotene and Retinol Efficacy Trial (CARET) for prevention of lung cancer. *Cancer Epidemiology, Biomarkers and Prevention* 5(2):815-821, 1996.
26. Women's Health Initiative Study Group. Design of the Women's Health Initiative Clinical Trial and Observational Study. *Controlled Clinical Trials* 19(1):61-109, 1998.
27. Wang CY, *Anderson GL*, Prentice R. Estimation of the correlation between nutrient intake measures under restricted sampling. *Biometrics* 55:711-717, 1999.
28. *Anderson GL* and Prentice RL. Individually randomized intervention trials for disease prevention and control. *Statistical Methods in Medical Research* 8:287-309, 1999.
29. Drescher C, Holt SK, Anderson MR, *Anderson G*, Urban N. Reported ovarian cancer screening among a population-based sample in Washington State. *Obstetrics and Gynecology* 96(1):70-74, 2000.

30. Johnson SR, *Anderson GL*, Barad DH, Stefanick ML. The Women's Health Initiative: Rationale, Design and Progress Report. *Journal of the British Menopause Society* 5:155-159, 2000.
31. Wassertheil-Smoller S, *Anderson G*, Psaty BM, Black HR, Manson J, Wong N, Francis J, Grimm R, Kotchen T, Langer R, and Lasser N. Hypertension and its treatment in postmenopausal women: baseline data from the Women's Health Initiative. *Hypertension* 36(5):780-789, 2000.
32. Crump C, Martin MW, Urban N, *Anderson G*, Karlan BY. Ovarian cancer tumor marker behavior in asymptomatic women and implications for screening. *Cancer Epidemiology, Biomarkers & Prevention* 9(10):1007-1111, 2000.
33. Liu PY, *Anderson G* and Crowley JJ. Observational Studies and Randomized Trials: Letter to the Editor. *New England Journal of Medicine* 343(16):1195, 2000.
34. The Writing Group for the Women's Health Initiative. Risks and benefits of estrogen plus progestin in healthy post-menopausal women. Principal results of the Women's Health Initiative randomized controlled trial. *Journal of the American Medical Association* 288(3):321-333, 2002.
35. Pepe MS, Longton G, *Anderson GL*, Schummer M. Selecting differentially expressed genes from microarray experiments. *Biometrics* 59:133-142, 2003.
36. Etzioni R, Urban N, Ramsey S, McIntosh M, Schwartz S, Reid B, Radich J, *Anderson G*, Hartwell L. The case for early detection. *Nat Rev Cancer* Apr;3(4):243-52, 2003.
37. Shikany JM, Patterson R, Tanya Agurs-Collins, *Anderson GL*. Antioxidant supplement use in Women's Health Initiative participants. *Preventive Medicine* 36(3):379-387, 2003.
38. Harris RE, Chlebowski RT, Jackson RD, Frid DJ, Ascenseo JL, *Anderson GL*, Loar A, Rodabough RL, White E, McTiernan A. Breast cancer and nonsteroidal anti-inflammatory drugs (NSAIDs): Prospective results from the Women's Health Initiative. *Cancer Research* 63:6096-6101, 2003.
39. *Anderson GL*, Judd H, Kaunitz A, Barad D, Beresford S, Pettinger M, Liu J, McNeeley SG, Lopez AM. Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures in the Women's Health Initiative. *JAMA* 290:1739-1748, 2003.
40. *Anderson GL*, Manson J, Wallace R, Lund B, Hall D, Davis S, Shumaker S, Wang CY, and Prentice RL. Implementation of the WHI study design. *Annals of Epidemiol* 13:S5-S17, 2003.
41. Hays J, Hunt JR, Hubbel A, *Anderson GL*, Limacher M, Allen C, Rossouw JE. The Women's Health Initiative recruitment methods and results. *Annals of Epidemiol* 13:S18-S77, 2003.
42. *Anderson GL*, Limacher M, Assaf A, et al. Effects of conjugated equine estrogens on postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. *JAMA* 291:1701-1712, 2004.
43. Prentice RL, *Anderson GL*. Women's Health Initiative: Statistical aspects and early results. *Encyclopedia of Biostatistics*, 2<sup>nd</sup> Edition, Armitage P and Colton T (editors), 2005.
44. Chlebowski RT, Chen Z, *Anderson GL*, Aragaki A, Dolan NC, Paskett E, et al. Ethnicity and breast cancer: Factors influencing differences in incidence and outcome. *J Natl Cancer Inst* 2005; 97(6):439-448.
45. Gass M, *Anderson GL*, Barad D. Concerns about published data from the estrogen-progestin (HT) arm of the WHI. *Am J Obstet Gynecol* 2005;192:333.
46. Chlebowski RT and *Anderson GL*. Progestins and recurrence in breast cancer survivors. *J Natl Cancer Inst*. 2005;97(7):471-472.
47. Stefanick ML, Prentice RL, *Anderson GL*, Gass M, Manson J. Reanalysis of WHI oral contraceptive data reveals no evidence of delayed cardiovascular benefit. *Fertil Steril* 2005;83(4):853-854.

48. Prentice RL, Langer RL, Stefanick M, Howard B, Pettinger M, *Anderson GL*, Barad D, Curb J, Kotchen J, Kuller L, Limacher M, Wactawski-Wende J, for the Women's Health Initiative Investigators. Combined postmenopausal hormone therapy and cardiovascular disease: toward resolving the discrepancy between the clinical trial and observational study in the Women's Health Initiative. *American Journal of Epidemiology* 2005;162:1-11.
49. Prentice RL, Pettinger M, *Anderson GL*. Statistical issues arising in the Women's Health Initiative (with commentary and response). *Biometrics* 2005;61:899-941.
50. Prentice RL, Langer RL, *Anderson G*, Barad D. Response to commentary: "How Far Can Epidemiologists Get With Statistical Adjustment?" *American Journal of Epidemiology* 2005;162:419-420.
51. Prentice RL, Caan B, Chlebowski R, Patterson R, Kuller L, Ockene J, Margolis K, et al (including *Anderson*). Low-fat dietary pattern and risk of invasive breast cancer: the Women's Health Initiative randomized controlled Dietary Modification trial. *JAMA* 2006;295:629-642.
52. Beresford SAA, Johnson KC, Ritenbaugh C, Lasser N, Snetselaar LG, Black HR, *Anderson GL*, et al. Low-fat dietary pattern and risk of colorectal cancer: the Women's Health Initiative randomized controlled Dietary Modification trial. *JAMA* 2006;295:643-654.
53. Howard BV, Van Horn L, Hsia J, Manson JE, Stefanick ML, Wassertheil-Smoller S, et al. (including *Anderson*). Low-fat dietary pattern and risk of cardiovascular disease: the Women's Health Initiative randomized controlled Dietary Modification trial. *JAMA* 2006;295:655-666.
54. Wactawski-Wende J, Kotchen JM, *Anderson GL*, Assaf AA, Brunner RL, O'Sullivan, MJ, et al. Calcium plus vitamin D supplementation and the risk of colorectal cancer. *NEJM* 2006;354:684-696.
55. Jackson RD, LaCroix AZ, Gass M, Wallace RB, Robbins, JR, Lewis CE, et al (including *Anderson*). Calcium plus vitamin D supplementation and the risk of fractures. *NEJM* 2006;354(7):669-683.
56. Prentice RL, Langer RL, Stefanick M, Howard B, Pettinger M, *Anderson GL*, Barad D, Curb J, Kotchen J, Kuller L, Limacher M, Wactawski-Wende J, for the WHI Investigators. Combined analysis of Women's Health Initiative observational and clinical trial data on postmenopausal hormone treatment and cardiovascular disease. *Am J Epidemiol* 2006;163:589-599.
57. Stefanick ML, *Anderson GL*, Margolis KL, Hendrix SL, Rodabough RJ, Paskett E, et al. Effects of conjugated equine estrogens on breast cancer and mammography in postmenopausal women with hysterectomy: the Women's Health Initiative randomized trial. *JAMA* 2006;295:1647-1657.
58. Scholler N, Crawford M, Sato A, Drescher CW, O'Briant KC, Kivat N, *Anderson GL*, Urban ND. Development of a CA125 bead-based ELISA assay for use in small volume serum samples. *Clinical Cancer Research* 2006;12:2117-2124
59. *Anderson GL*, Chlebowski RT, Rossouw JE, Rodabough RJ, McTiernan A, Margolis KL, et al. Prior hormone therapy and breast cancer risk in the WHI estrogen plus progestin trial. *Maturitas* 2006;55(2):103-115.
60. Sato AH, *Anderson GL*, Urban N, McIntosh MW. Comparing adaptive and non-adaptive algorithms for cancer early detection with novel biomarkers. *Disease Biomarkers* 2006;2:151-162.
61. Chlebowski RT, Anderson GL, Geller M, Col N. Coronary heart disease and stroke with aromatase inhibitor, tamoxifen, and menopausal hormone therapy use. *Clin Breast Cancer*. 2006; 2:S58-64.
62. Miller KA, Siscovick DS, Sheppard L, Shepherd K, Sullivan JH, *Anderson GL*, Kaufman J. Long-term exposure to fine particulate matter air pollution and cardiovascular events in women. *NEJM* 2007;356(5):447-458.

63. Anderson GL, Kooperberg C, Geller N, Rossouw JE, Pettinger M, Prentice RL. Monitoring and reporting in the Women's Health Initiative randomized hormone therapy trials. *Clinical Trials* 2007;4:207-217.
64. Prentice RL, Thomson CA, Caan B, Hubbell FA, *Anderson GL*, Beresford SAA, et al. Low-fat dietary pattern and cancer incidence in the Women's Health Initiative Dietary Modification trial. *J Natl Cancer Inst* 2007;99:1534-1543.
65. Chlebowski RT, *Anderson GL*, Lane DS, Aragaki AK, Rohan T, Yasmeeen S, Sarto G, et al. Predicting risk of breast cancers in postmenopausal women by hormone receptor status. *J Natl Cancer Inst* 2007;99:1695-1705.
66. Thorpe JD, Duan X, Forrest R, Lowe K, Brown L, Segal E, et al (including *Anderson*). Effects of blood collection conditions on ovarian cancer serum markers. *PLoS ONE* 2007;2(12):e1281.
67. Gail MH, Costantino JP, Pee D, Bondy M, Newman L, Selvan M, et al (including *Anderson*). Projecting individualized absolute invasive breast cancer risk in African American Women: Data from the Women's Contraceptive and Reproductive Experiences (CARE) study. *J Natl Cancer Inst* 2007;99(23):1782-1792.
68. Chlebowski RT, *Anderson G*, Pettinger M, Lane D, Langer RD, Gillian MA, Walsh BW, Chen C, McTiernan A, for the Women's Health Initiative Investigators. Estrogen Plus Progestin and Breast Cancer Detection by Means of Mammography and Breast Biopsy. *Arch Intern Med*. 2008;168(4):370-7.
69. Heiss G, Wallace R, *Anderson GL*, Aagaki A, Bryski R, Gass M, et al. Health Risks and Benefits Three Years After Stopping Randomized Treatment with Estrogen and Progestin. *JAMA* 2008;299(9):1036-1045.
70. Prentice RL, Chlebowski RT, Stefanick ML, Manson JE, Pettinger M, Hendrix SL, Hubbell FA, Kooperberg C, Kuller LH, Lane DS, McTiernan A, O'Sullivan MJ, Rossouw JE, *Anderson GL*. Estrogen Plus Progestin Therapy and Breast Cancer in Recently Postmenopausal Women. *Am J Epidemiol*. 2008;167(10):1207-1216.
71. Prentice RL, *Anderson GL*. The Women's Health Initiative: Lessons learned. *Annual Rev Public Health* 2008;29:131-150, 2008. [Exempt from PMC requirements; contract in place before 4/7/08]
72. Gunter MJ, Hoover DR, Yu H, Wassertheil-Smoller S, Manson JE, Li J, Harris TG, Rohan TE, Xue X, Ho GY, Einstein MH, Kaplan RC, Burk RD, Wylie-Rosett J, Pollak MN, Anderson G, Howard BV, Strickler HD. A Prospective Evaluation of Insulin and Insulin-like Growth Factor-I as Risk Factors for Endometrial Cancer. *Cancer Epidemiol Biomarkers Prev*. 2008;17(4):921-9. [Exempt from PMC requirements; contract in place before 4/7/08]
73. Scholler N, Lowe KA, Bergan LA, Kampani AV, Ng V, Forrest RM, Thorpe JD, Gross JA, Garvik BM, Drapkin R, *Anderson GL*, Urban N. Use of yeast-secreted in vivo biotinylated recombinant antibodies (biobodies) in bead-based ELISA. *Clin Cancer Res*. 2008;14(9):2647-55. [PMCID: 2744596]
74. Prentice RL, Chlebowski RT, Stefanick ML, Manson JE, Langer RD, Pettinger M, et al (including *Anderson*). Conjugated equine estrogens and breast cancer risk in the Women's Health Initiative clinical trial and observational study. *Am J Epidemiol*. 2008;167(12):1407-1415. [PMCID: 2703736]

75. Thomson CA, Neuhouser ML, Shikany JM, Caan BJ, Monk BJ, Mossavar-Rahmani Y et al, (including *Anderson*). The role of antioxidants and vitamin A in ovarian cancer: results from the Women's Health Initiative. *Nutrition and Cancer, Nutr Cancer*. 2008;60(6):710-9.
76. McIntosh M, Anderson GL, Brown P, Coukos G, Drescher CW, Gambhir SS, Hanash S, Laird P, Nelson B, Palmer C, Urban N. Letter to the Editor: Ovarian Cancer Early Detection Claims are Biased. *Clin Cancer Res*. 2008;14(22):7574. [Exempt from PMC requirements; contract in place before 4/7/08]
77. Lowe K, Shah C, Wallace E, *Anderson G*, Paley P, McIntosh M, Andersen R, Scholler N, Bergan L, Thorpe J, Urban N, Drescher C. Personal characteristics influence Serum CA125, mesothelin, and HE4 levels in healthy postmenopausal women at increased risk for ovarian cancer. *Cancer Epidemiol Biomarkers Prev* 2008;17(9):2480-7. [PMCID: 2632599]
78. Gunter MJ, Hoover DR, Yu H, Wassertheil-Smoller S, Rohan TE, Manson JE, et al (including *Anderson*) Insulin, Insulin-like Growth Factor-I, Endogenous Estradiol and Risk of Colorectal Cancer. *Cancer Res*. 2008;68(1):329-37. [Exempt from PMC requirements; contract in place before 4/7/08]
79. Gunter MJ, Hoover DR, Yu H, Wassertheil-Smoller S, Rohan TE, Manson JE, Li J, Ho GY, Xue X, Anderson GL, Kaplan RC, Harris TG, Howard BV, Wylie-Rosett J, Burk RD, Strickler HD. Insulin, insulin-like growth factor-I, and risk of breast cancer in postmenopausal women. *J Natl Cancer Inst*. 2009;101(1):48-60. [PMCID:2639294]
80. Liao D, Whitsel EA, Duan Y, Lin HM, Quibrera PM, Smith R, Pequet DJ, Prineas RJ, Zhang ZM, *Anderson G*. Ambient particulate air pollution and ectopy: The environmental epidemiology of arrhythmogenesis in Women's Health Initiative Study, 1999-2004. *J Toxicol Environ Health A*. 2009;72(1):30-8. [PMCID:2586923]
81. Zhang Z, Whitsel EA, Quibrera PM, Smith RL, Liao D, Anderson GL, Prineas RJ. Ambient fine particulate matter exposure and myocardial ischemia in the Environmental Epidemiology of Arrhythmogenesis In the Women's Health Initiative (EEAWHI). *Environ Health Perspect*. 2009; 117(5):751-6. [PMCID:2685837]
82. Chlebowski RT, Kuller LH, Prentice RL, Stefanick ML, Manson JE, Gass M, Aragaki AK, Ockene J, Lane DS, Sarto GE, Rajkovic A, Schenken R, Hendrix SL, Ravdin PM, Rohan TE, Yasmeen S, *Anderson G*. Breast Cancer after Estrogen plus Progestin Use in Postmenopausal Women. *NEJM* 2009;360:573-87. [Exempt from PMC requirements; contract in place before 4/7/08]
83. Neuhouser ML, Wassertheil-Smoller S, Thomson C, Aragaki A, Anderson GL, Manson JE, et al. Multivitamin use and risk of cancer and cardiovascular disease in the Women's Health Initiative Cohorts. *Arch Intern Med* 2009;169:294-304.
84. Whitsel EA, Quibrera PM, Christ SL, Liao D, Prineas RJ, Anderson GL, Heiss G. Heart rate variability, ambient particulate matter air pollution, and glucose homeostasis: The Environmental Epidemiology of Arrhythmogenesis in the Women's Health Initiative. *Am J Epidemiol*. 2009;169(6):693-703. [PMCID:2732976]
85. LaCroix AZ, Kotchen J, *Anderson GL*, Bryzski B, Cauley J, Cummings SR, Gass M, Johnson KC, Ko M, Larson J, Manson JE, Stefanick M, Wactawski-Wende J. Calcium plus Vitamin D Supplementation and Risk of Death in Postmenopausal Women: The WHI Calcium-Vitamin D

- Randomized Controlled Trial. *J Gerontol A Biol Sci Med Sci.* 2009;64(5):559-67. [PMCID:2800808]
86. Ahmed S, Thomas G, Ghousaini M, et al (including Anderson) Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. *Nature Genetics* 2009;41(5):585-90. [PMCID:2748125]
  87. Shah CA, Lowe KA, Paley P, Wallace E, *Anderson GL*, McIntosh MW, et al. Influence of ovarian cancer risk status on the diagnostic performance of the serum biomarkers mesothelin, HE4 and CA125. *Cancer Epidemiol Biomarkers Prev* 2009;18(5):1365-72. [PMCID:2714056]
  88. Prentice RL, Manson JE, Langer RD, Anderson GL, Pettinger M, Jackson RD, Johnson KC, Kuller LH, Lane SD, Wactawski-Wende J, Brzyski R, Allison M, Okene J, Sarto G, Rossow JE. Benefits and Risks of Postmenopausal Hormone Therapy when Initiated Soon After the Menopause. *Am J Epidemiol.* 2009;170(1):12-23. [PMCID:2733042]
  89. Smith HO, Moon J, Wilczynski SP, Tiersten AD, Hannigan EV, Robinson WR, Rivkin SE, *Anderson GL*, Liu PY, Markman M. Southwest Oncology Group Trial S9912: Intraperitoneal cisplatin and paclitaxel plus intravenous paclitaxel and pegylated liposomal doxorubicin as primary chemotherapy of small-volume residual stage III ovarian cancer. *Gynecologic Oncology* 2009;114(2):206-9. [PMCID:2703693]
  90. Crandall CJ, Aragaki AK, Chlebowski RT, McTiernan A, *Anderson G*, Hendrix SL, Cochrane BB, Langer RD, Kuller L, Cauley JA. New-onset breast tenderness after initiation of estrogen plus progestin hormone therapy and future breast cancer risk: The Women's Health Initiative Estrogen Plus Progestin Trial. *Arch Intern Med.* 2009;169(18):1684-1691.
  91. Chlebowski RT, Schwartz AG, Wakelee H, *Anderson GL*, Stefanick ML, Manson JE, Rodabough RJ, Chien JW, Wactawski-Wende J, Gass M, Kotchen JM, Johnson KC, O'Sullivan MJ, Ockene JK, Chen C, Hubbell FA, for the Women's Health Initiative Investigators. Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative trial): a post-hoc analysis of a randomised controlled trial. *Lancet.* 2009;374:1243-1251. [Exempt from PMC requirements; contract in place before 4/7/08]
  92. *Anderson GL*, McIntosh M, Wu L, Bergan L, Thornquist MD, Scholler N, Kim N, O'Briant K, Drescher C, Urban N. Assessing lead time of selected ovarian cancer biomarkers: a nested case-control study. *J Natl Cancer Inst* 2010;102:26-38. [PMCID:2802285]
  93. Wolpin BM, Kraft P, Gross M, et al (including *Anderson*). Pancreatic cancer risk and ABO blood group alleles: Results from the Pancreatic Cancer Cohort Consortium. *Cancer Res.* 2010 Jan 26. [Epub ahead of print] [Exempt from PMC requirements; contract in place before 4/7/08]
  94. Edlefsen KL, Jackson RD, Prentice RL, Janssen I, Rajkovic A, O'Sullivan MJ, and *Anderson G*. The effects of postmenopausal hormone therapy on serum estrogen, progesterone and sex hormone-binding globulin levels in healthy postmenopausal women. *Menopause.* 2010 Mar 3. [NIHMS172843] [PMCID: PMC2866828]
  95. Chlebowski RT, Chen Z, Cauley JA, Anderson G, Rodabough RJ, McTiernan A, Lane DS, Manson JE, Snetelaar, Yasmeen LS, O'Sullivan MJ, Safford M, Hendrix SL, and Wallace RB. Oral bisphosphonate use and breast cancer incidence in postmenopausal women. *J Clin Oncol.* 2010 Jun 21. [PMCID: PMC2917313]

Anderson GL

96. Anderson GL. Ovarian cancer biomarker screening: still too early to tell. *Women's Health* 2010;6(4):487–490.
97. Chlebowski RT, Anderson GL, Stefanick M, Manson J, et al. Estrogen Alone and Breast Cancer Detection by Means of Mammography and Breast Biopsy. *Journal of Clinical Oncology*, 2010; 28(16) 2690-2697. [PMCID: PMC2881849]
98. Markman M, Moon J, Wilczynski S, Lopez AM, et al (including Anderson). Single agent carboplatin versus carboplatin plus pegylated liposomal doxorubicin in recurrent ovarian cancer: Final survival results of a SWOG (S0200) phase 3 randomized trial. *Gynecologic Oncology* 2010;116:323-325.
99. Chlebowski RT, Anderson GL, Manson JE, Schwartz AG, Wakelee H, Gass M, Rodabough RJ, Johnson KC, Wactawski-Wende J, Kotchen JM, Ockene JK, O’Sullivan MJ, Hubbell FA, Chien JW, Chen C, Stefanick ML. Lung cancer among postmenopausal women treated with estrogen alone in the Women’s Health Initiative Randomized Trial. *J Natl Cancer I*. 2010 Aug 13. [Epub ahead of print]
100. Chlebowski RT, Anderson GL, Gass M, Lane DS, Aragaki AK, Kuller LH, Manson JE, Stefanick ML, Ockene J, Sarto GE, Johnson KC, Wactawski-Wende J, Ravdin PM, Schenken R, Hendrix SL, Rajkovic A, Rohan TE, Yasmeen S, Prentice RL, for the WHI Investigators. Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. *JAMA*. 2010;304(15):1684-1692.
101. Freeman EW, Guthrie KA, Caan B et al (including Anderson). Efficacy of escitalopram for menopausal hot flashes: A randomized controlled trial in the MsFlash Network. *JAMA*, accepted.

### Submitted Manuscripts

Matsuno RK, Costantino JP, Zeigler RG, Anderson GL, Li H, Pee D, and Gail M. Projecting individualized absolute invasive breast cancer risk in Asian and Pacific Islanders. Submitted to JNCI.

Freedman AN, Yu B, Gail MH, et al (including Anderson). Benefit/Risk Assessment for Breast Cancer Chemoprevention With Raloxifene or Tamoxifen for Women Age 50 Years and Older.. Submitted to JCO.

Bodelon C, Anderson GL, Rossing MA, Chlebowski RT, Ochs-Balcom HM, Vaughan TL. Hormonal factors and risks of esophageal squamous cell carcinoma and adenocarcinoma in postmenopausal women. Submitted to Cancer Prevention.

Chlebowski RT and Anderson GL. Time-from-menopause and mammography influence on menopause hormone therapy breast cancer risk assessment. Submitted to JNCI.

Greenberg ER, Anderson GL, Morgan D, et al. A randomized trial comparing 14-day triple, 5-day concomitant, and 10-day sequential therapies to eradicate *Helicobacter pylori* in seven Latin American populations. Submitted to NEJM.

### MANUSCRIPTS IN DEVELOPMENT:

Anderson GL et al. Menopausal hormones and risk of ovarian cancer: results from the Women's Health Initiative randomized trial and observational study.

Crandall CK, Aragaki AK, Cauley JA, et l (including Andereson). Associations of New-Onset Breast Tenderness and Subsequent Breast Cancer Risk during Estrogen-Alone versus Estrogen Plus Progestin Therapy

Anderson GL et al. Cumulative and post-cessation effects of estrogen therapy on breast cancer incidence in postmenopausal women: The Women's Health Initiative randomized trial

### **BOOK CHAPTERS:**

1. Urban, N, McIntosh M, Clarke L, Jacobs I, Karlan B, *Anderson G*, Drescher D. Socio-economics of ovarian cancer screening. *Ovarian Cancer* 6. Oxford University Press, 2002.
2. *Anderson GL*, Leblanc M, Liu PY, Crowley J. On use of covariates in randomization and analysis of clinical trials. *Handbook of Statistics in Clinical Oncology*, 2nd ed. Ankerst DP and Crowley J, editors. Chapman and Hall/CRC Press, Boca Raton, 2006.
3. *Anderson GL*. Lifestyle and breast cancer: A review of randomized trials. *Breast Cancer: Prevention and Early Detection*, Sauter E and Daly MB, editors. Springer Science+Business Media, LLC, New York, 2010.
4. *Anderson GL* and Prentice RL. Understanding the effects of postmenopausal hormone therapy. Using the Women's Health Initiative randomized trials and observational study to improve inference. In *Causality and Psychopathology: Finding the determinants of disorders and their cures*, Shrout PE, Keyes KM and Ornstein, editors. Oxford University Press, 2011.

### **OTHER PUBLICATIONS:**

1. *Anderson GL*, Rossouw JE, Oberman A, Editors. The Women's Health Initiative Baseline Summary. *Annals of Epidemiology Supplement*, 2003.

### **PRESENTATIONS:**

1. On Misspecified Cox Proportional Hazards Models. Contributed presentation to the International Biometrics Conference, Hamilton, New Zealand, 1992.
2. Toward More Comprehensive Data Management in Multicenter Studies: The Women's Health Initiative Example. Invited presentation to the Society for Controlled Clinical Trials, Houston TX, 1994.
3. Distributed Data Management Systems: Making them do more of the work for everyone. Invited pre-conference workshop for the Society for Controlled Clinical Trials, Pittsburgh PA, 1996.
4. Multiple Endpoints and Multiple Trials: Data Monitoring in the Women's Health Initiative. Invited presentation to the American College of Epidemiology, Boston MA, 1997.
5. An update on the Women's Health Initiative. Invited presentation to the Department of Biostatistics, University of Washington, Seattle WA February 1998.
6. The Other Women in Science: Women of the Women's Health Initiative. Invited presentation to the Association for Women in Science, Seattle WA, 1998.

7. Issues in the design and conduct of prevention trials. Invited presentation to the Cancer Genetics Network, Salt Lake City UT, 2000.
8. Novel Technologies for Discovery of Markers for Use in Screening for Ovarian Cancer, Invited presentation with Nicole Urban, Michel Schummer and Brad Nelson, to the Department of Defense Ovarian Cancer Investigators' Forum, Washington DC, November 30, 2000.
9. Data collection with Optical Mark Recognition Scanners. A workshop presentation for the Society of Clinical Trials, Denver CO, May 2001.
10. Selecting Differentially Expressed Genes from Microarray Experiments. Annual meeting of the SPORE program, Washington DC, July 2001.
11. Leveraging Prevention Trials: Ovarian cancer screening and the Women's Health Initiative. PHS Informal Faculty Seminar, Fred Hutchinson Cancer Research Center, Seattle WA, January 2002.
12. Report on the Women's Health Initiative. Invited presentation to Endocrine Days, Ocean Shores WA, September 2002.
13. The Statistical Issues Surrounding the Women's Health Initiative Clinical Trial. Invited presentation to the annual meeting of the American Society of Reproductive Medicine, Seattle WA, October 2002.
14. Breast Cancer Risk as the Catalyst for the Early Stopping of the Women's Health Initiative Randomized Trial of Estrogen Plus Progestin, Invited presentation to Cancer 2002: Early Intervention, Fox Chase Cancer Center, Philadelphia PA, October 2002.
15. Statistical Issues in the Early Stopping and Reporting of the WHI Estrogen Plus Progestin Randomized Trial. Invited seminar, University of Washington Department of Biostatistics, Seattle, WA, October 2002.
16. Risks and Benefits of Estrogen Plus Progestin: Results of the WHI Randomized Prevention Trial. FHCRC Grand Rounds, November 2002.
17. Trials of Prevention: Making the case for prevention trials. Invited seminar, University of Utah, School of Medicine, Division of Reproductive Endocrinology and Infertility. March 2003.
18. Hormones and Women's Health: A view from the Women's Health Initiative. Sixth Annual A. Marsh Poulson, Jr. MD. Lectureship, University of Utah, School of Medicine, Division of Reproductive Endocrinology and Infertility. March 2003.
19. An update on gynecologic cancer research in the Women's Health Initiative. Invited seminar, Gynecologic Cancer Research Program, FHCRC. April 2003.
20. Prevention Trial Design, Monitoring and Analysis: Example of the Women's Health Initiative, with Ross Prentice. Wade Hampton Frost Society Annual Lecture, Johns Hopkins School of Public Health, Baltimore MD. April 2003.
21. Women's Health Initiative Study, its background and the breast cancer and cardiovascular results. Invited presentation to the Annual Carroll W. Feist Scientific Symposium, Feist-Weiller Cancer Center, Shreveport LA. May 2003.
22. Logistical challenges and approaches in large prevention trials: An example from the Women's Health Initiative. Invited seminar to The Johns Hopkins Center for Clinical Trial, Baltimore MD. May 2003.
23. Hormones and Women's Health: A view from the Women's Health Initiative. Invited seminar to the Hoag Hospital Foundation. Hoag Hospital, Newport Beach CA. May 2003.
24. Risks and benefits of estrogen plus progestin: An updated assessment. Invited seminar, Hoag Hospital, Newport Beach CA. May 2003.

25. Statistical issues in the reassessment of postmenopausal hormones: Aftermath of the Women's Health Initiative randomized trial of estrogen plus progestin. Joint Statistical Meetings, San Francisco. August 2003.
26. Developing models of ovarian cancer risk. Invited presentation to the National Ovarian Cancer Coalition, San Francisco. September 2003.
27. Update on the Hormone Therapy Trials in the Women's Health Initiative. Invited seminar for the UW Reproductive Medicine Department. Seattle. September 2003.
28. Estrogen plus progestin increases risk of breast cancer and abnormal mammograms: Findings from the Women's Health Initiative randomized trial. Invited presentation for the UW Breast Cancer Continuing Medical Education, Seattle. October 2003.
29. Menopausal Hormone Therapy—Is There Cardiovascular Protection? The Latest Clinical Trial Data. Invited presentation for the Women and Heart Disease CME Symposium, Somerset, New Jersey. October 2003.
30. The Women's Health Initiative: Overview and early results. Invited lecture for UW Biostatistics 514, Seattle. November 2003.
31. Evidence and Uncertainty: Statistical Thinking in WHI Findings on HRT. Invited presentation to the American Association for the Advancement of Science, Seattle. February 2004.
32. Biomarkers for ovarian cancer screening and risk: A research strategy. Invited lecture to Ovarian Cancer Research Group, Huntsman Cancer Institute, Salt Lake City. April 2004.
33. The Women's Health Initiative: Overview and early results. Invited lecture for UW Biostatistics 514, Seattle. June 2004.
34. Some considerations for layering biomarker validation research onto prevention trials and large cohort studies. Invited presentation to the NCI-FDA sponsored workshop "Research Strategies, Study Designs and Statistical Approaches to Biomarkers Validation for Cancer Diagnosis and Detection," Washington DC. July 2004.
35. Women's Health Initiative and lung cancer research: Opportunities for collaborative research. Invited presentation to the FHCRC Lung Cancer Affinity Group, Seattle. August 2004.
36. Estimating risk of ovarian cancer. Invited presentation to the American Association for Cancer Research meeting, Frontiers in Cancer Prevention, Seattle. October 2004.
37. Publication and Dissemination: Special issues in multi-site trials. Invited presentation to Multisite Clinical Trials in Rehabilitation Medicine conference, Denver. October 2004.
38. Estrogen alone and other hormone sagas: An update from the Women's Health Initiative. Presentation to the Clinical Trials Affinity Group, FHCRC. November 2004.
39. Statistical complexities and controversies in randomized trials: Examples from the Women's Health Initiative. Invited Seminar, Department of Biostatistics, University of North Carolina, Chapel Hill. February 2005.
40. Estrogen, Estrogen plus Progestin and Cardiovascular Disease. Invited presentation to the International Breast Cancer Congress, Southampton, Bermuda. July 2005.
41. Menopausal hormones and low-fat diet: An update from the Women's Health Initiative. Grand Rounds, Department of Obstetrics and Gynecology, University of Washington, February 2006.
42. Clinical Validation and Performance Assessment of Biomarkers for Early Detection. Invited presentation to SPORE Workshop, Baltimore, July 2006.

43. Enhancing inference from clinical studies with biomarker data. Invited presentation to SPORE workshop entitled: Strategies for implementing biomarker evidence in translational cancer research, Baltimore, July 2007.
44. Estimating Risk of Ovarian Cancer. Invited presentation to SPORE Workshop Ovarian Cancer breakout session, Baltimore, July 2007.
45. Hormone therapy effects on clinical outcomes and quality of life: Results of the Women's Health Initiative randomized trials. Invited presentation, with Aaron Aragaki, to the Biobehavioral Affinity Group. Seattle, February 2008.
46. Lessons from The Women's Health Initiative. Invited presentation to the American Psychopathological Association Meeting, New York, March 2008
47. A preliminary assessment of ovarian cancer biomarkers for risk and early detection. Invited presentation to the Canary Foundation Symposium. Stanford, May 2008
48. Estimating risk of ovarian cancer. Invited presentation to the Gynecologic Oncology department at Princess Margaret Hospital. Toronto, November, 2008
49. Hormone therapy and Chronic Disease: An update from the Women's Health Initiative. Invited presentation to the Department of Obstetrics and Gynecology, University of Toronto. Toronto, November, 2008
50. Reconciling observational studies and randomized clinical trials: The hormone therapy example from the Women's Health Initiative. Invited presentation to the Department of Biostatistics, University of Copenhagen. Copenhagen, February 2010.
51. The Women's Health Initiative RCT of Calcium and Vitamin D Supplements in Postmenopausal Women. Invited presentation to the Cancer Prevention Committee, Southwest Oncology Group Meeting. San Francisco, April 2010.
52. Assessing lead time of selected ovarian cancer biomarkers. Invited presentation to the Women's Cancer Research Program, Fred Hutchinson Cancer Research Center. Seattle, April 2010.
53. When research studies lead to litigation, what are the consequences for researchers? Lessons learned from WHI. Joint presentation (with Campbell and Sands) to the Clinical Trials Affinity Group, Fred Hutchinson Cancer Research Center, Seattle, June 2010.
54. The Women's Health Initiative: Design and Data. Invited presentation to the NHLBI-Northwestern University Cohort Studies Workshop. Chicago, July 2010.
55. When research studies lead to litigation, what are the consequences for researchers? Lessons learned from WHI. Invited presentation (with Campbell and Sands) to the Cardiovascular Health Research Unit, University of Washington, Seattle, September 2010.
56. When research studies lead to litigation, what are the consequences for researchers? Lessons learned from WHI. Invited presentation (with Campbell and Sands) to the Group Health Research Institute, Seattle, September 2010.
57. The Women's Health Initiative: Design and Data. Invited presentation to the North American Menopause Society Pre-conference Workshop. Chicago, October 2010.
58. Practical Issues in the Conduct and Reporting of Large-Scale Clinical Trials: The Women's Health Initiative Experience (with Andrea LaCroix). Invited pre-conference workshop to the Fourth Seattle Symposium. Seattle, November 2010.

Anderson GL

**SUBMITTED FUNDING PROPOSALS:**

**NHLBI-WH-11-11 (Anderson)**

*Dates of Entire Project:* 04/01/11 – 03/31/16

NIH: Women's Health Initiative Clinical Coordinating Center

*Annual Direct Costs:* \$11,602,517

Role/effort in Project: Principal Investigator 40%

**CURRENT FUNDING:**

**N01 WH-2-2110 (Prentice)**

*Dates of Entire Project:* 09/30/92 – 03/31/11

NIH: Women's Health Initiative Clinical Coordinating Center

*Annual Direct Costs:* \$10,388,400

Role in Project: Co-Principal Investigator 40%

**U01 HG0047901-01 (Kooperberg)**

*Dates of Entire Project:* 07/17/08 – 05/31/12

NHGRI/NCI: Epidemiology of Putative Genuine Genetic Variants: The Women's Health Initiative

*Annual direct costs: \$1,093,576 (year 1 direct costs)*

Role/effort in Project: Co-Investigator 2%

**U01 AG032699-01 (LaCroix and Anderson)**

*Dates of Entire Project:* 09/15/08 – 06/30/13

NIH/NIA: Menopausal Symptoms -- Finding Lasting Answers for Sweats and Hot Flashes

*Annual direct costs: \$2,028,335*

Role/effort in Project: Co-Principal Investigator 20%

**Grant Proposal #43930 (Laurence Baker)**

*Dates of Entire Project:* 10/10/08 – 9/30/10

Bill and Melinda Gates Foundation Global Health Program

*Total project costs: \$2,850,376*

Role/effort in Project: Co-Investigator 10%

**U01 CA37429 (Laurence Baker)**

*Dates of Entire Project:* 6/01/01 – 5/31/10

CCOP Community Clinical Oncology Program

*Total project costs: \$419,815*

Role/effort in Project: Co-Investigator 5%

**BAA-NHLBI-WH-09-01 (McIntosh)**

*Dates of Entire Project:* 01/15/09 – 01/14/11

NIH/NHLBI: Discovery and Confirmation of Cancer Specific Serum Protein Markers for Ovarian Cancer Early Detection

*Total direct costs: \$661,055*

Role/effort in Project: Co-Investigator 2%

**NIH 1U01HG005152 (Reiner)**

*Dates of Entire Project:* 09/30/09 – 8/31/12

NHGRI/NCI: GWAS of Hormone Treatment and CVD and Metabolic Outcomes in the WHI

*Total direct costs: \$1,563,732*

Anderson GL

Role/effort in Project: Co-Investigator 2%

**5 U10 CA38926 (Crowley)**

*Dates of Entire Project:* 01/01/10 - 12/31/15

National Institutes of Health/National Cancer Institute

*Annual Direct Costs:* \$4,229,824

Role/effort in Project: Co-Investigator/Statistician 15%

**Statistical methods for evaluating markers for treatment selection (PI: Holly Janes)**

*Dates of entire project:* 7/1/10-6/30/14

NIH

Role/effort in Project: Co-Investigator 5%

**RECENT FUNDING:**

**P50 CA83636 (Urban)**

*Dates of Entire Project:* 09/30/99 – 06/30/09

NIH/NCI: Pacific Ovarian Cancer Research Consortium/SPORE in Ovarian Cancer

*Annual Direct Costs:* \$1,727,230

Role/effort in Project:

Project leader for Project 2: Estimating risk of ovarian cancer 15%

Co-leader of Informatics Core 5%

**Supplement to P50 CA 83636 (Urban)**

*Dates of Entire Project:* 09/30/02 - 06/30/09

NIH/NCI: Validation of a Biomarker Panel for Early Detection of Breast Cancer in High-Risk Women

*Annual Direct Costs:* \$144,494 (initial direct)

Role/effort in Project: Co-Investigator 5%

**BC013002 (Urban)**

*Dates of Entire Project:* 09/23/02 - 09/22/08 (NCE)

DOD/CDMRP : Center for the Evaluation of Biomarkers for the Early Detection of Breast Cancer

*Annual direct costs* \$1,114,579

Role/effort in Project: Co-Investigator 5%

**1 R01 ES012238-01 (Whitsel)**

*Dates of Entire Project:* 09/08/03 - 06/30/07

NIH: Environmental Epidemiology of Arrhythmogenesis in WHI

*Annual Subcontract Direct Costs:* \$30,817

Role/effort in Project: Principal Investigator of FHCRC subcontract 2.5%

**R01 CA93881-01 (Strickler)**

*Dates of Entire Project:* 01/15/02 - 12/31/05

NIH: Association of Diabetes and Insulin-like Growth Factor-I with Risks of Colorectal, Breast and Endometrial Cancers

*Annual Subcontract Direct Costs:* \$22,000

Role/effort in Project: Principal Investigator of FHCRC subcontract 2.5%

**1R21CA95113-01 (Modugno)**

*Dates of Entire Project:* 01/01/03 - 12/31/04

Anderson GL

NCI: Hyperinsulinemia and Ovarian Cancer

Annual Subcontract Direct Costs: \$32,000

Role/effort in Project: Principal Investigator of FHCRC subcontract 2.5%

**R01 CA96976 (Urban)**

Dates of Entire Project: 07/01/03 - 06/30/04

NIH/NCI: Modeling ovarian cancer screening for CEA

Annual direct costs \$166,250

Role/effort in Project: Co-Investigator 5%

**R827355 (Kaufman)**

Dates of Entire Project: 05/01/02 - 04/30/04

US Environmental Agency: Effect of Airborne Particulate Matter and Other Air Pollutants on the Incidence of Cardiovascular Events in the Women's Health Initiative Observational Study

Annual Subcontract Direct Costs: \$14,500

Role/effort in Project: Principal Investigator of FHCRC subcontract 1%

**SOUTHWEST ONCOLOGY GROUP PROTOCOLS:**

**Open:**

S0701: A randomized phase III trial of three antibiotic regimens to eradicate helicobacter pylori

S0809: A phase II trial of adjuvant capecitabine/gemcitabine chemotherapy followed by concurrent capecitabine and radiotherapy in extrahepatic cholangiocarcinoma

S0904: A randomized phase II study of docetaxel vs docetaxel and ZD6474 (vandetanib) in patients with persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma

**Approved:**

S0812: A Randomized Double-Blind Placebo-Controlled Biomarker Modulation Study of High Dose Vitamin D in Premenopausal Women at High Risk for Breast Cancer, Phase IIB

S0820: A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon Cancer, Phase III

**MENOPAUSAL SYMPTOMS- FINDING LASTING ANSWERS TO SWEATS AND HOT FLASHES (MSFLASH) PROTOCOLS:**

**Closed:**

MsFLASH 01: Efficacy of a Selective Serotonin Reuptake Inhibitor (SSRI) for Menopausal Symptoms in Midlife Women (PI: Ellen Freeman)

**Active:**

MsFLASH 02: Interventions for Relief of Menopausal Symptoms: A 3 by 2 Factorial Design Examining Yoga, Exercise, and Omega-3 Supplementation (PI: Andrea LaCroix)

**Pending:**

MsFLASH 02.1 An ultra-low-dose estrogen gel trial for women with vasomotor symptoms after an exercise/yoga intervention (PI: Susan Reed)

